(Q46533468)

English

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial

scientific article published on 18 June 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

1 reference

based on heuristic

inferred from title

author name string

Mathias Zink

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

A Kuwilsky

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

B Krumm

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

H Dressing

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

language of work or name

0 references

publication date

18 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

23

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

305-314

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

Ziprasidone: the fifth atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Prolactin elevation with ziprasidone.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Drug-induced prolongation of the QT interval

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Multiple antipsychotic medication prescribing patterns

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Metabolic drug interactions with newer antipsychotics: a comparative review.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Ziprasidone in the management of schizophrenia : the QT interval issue in context

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Clozapine versus typical neuroleptic medication for schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Combination of ziprasidone and clozapine in treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Ziprasidone-augmentation of clozapine

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Augmentation With a Second Antipsychotic in Patients With Schizophrenia Who Partially Respond to Clozapine

1 reference

https://api.crossref.org/works/10.1177%2F0269881108089593

21 January 2018

Identifiers

10.1177/0269881108089593

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18562423

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46533468&oldid=2116881143"